Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 2104.77 | 578 / 578 | 99% | 79.18 | 1146 / 1155 |
stomach | 97% | 1080.83 | 347 / 359 | 99% | 48.46 | 283 / 286 |
ovary | 97% | 681.12 | 175 / 180 | 97% | 38.51 | 417 / 430 |
intestine | 95% | 2286.98 | 919 / 966 | 98% | 50.44 | 519 / 527 |
bladder | 100% | 723.90 | 21 / 21 | 91% | 37.37 | 457 / 504 |
uterus | 93% | 471.94 | 158 / 170 | 95% | 35.58 | 435 / 459 |
adrenal gland | 97% | 568.86 | 251 / 258 | 88% | 25.01 | 203 / 230 |
breast | 88% | 646.07 | 406 / 459 | 96% | 39.59 | 1078 / 1118 |
skin | 87% | 437.67 | 1573 / 1809 | 97% | 51.40 | 457 / 472 |
thymus | 97% | 937.52 | 631 / 653 | 86% | 34.16 | 518 / 605 |
kidney | 100% | 841.57 | 89 / 89 | 82% | 25.26 | 740 / 901 |
esophagus | 91% | 469.40 | 1310 / 1445 | 88% | 33.76 | 161 / 183 |
prostate | 100% | 696.58 | 244 / 245 | 77% | 14.06 | 389 / 502 |
brain | 91% | 874.15 | 2404 / 2642 | 74% | 14.75 | 524 / 705 |
liver | 84% | 469.37 | 190 / 226 | 61% | 14.80 | 249 / 406 |
pancreas | 38% | 134.88 | 125 / 328 | 94% | 32.62 | 168 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 575.87 | 29 / 29 |
spleen | 100% | 13968.72 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 9528.22 | 926 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 96% | 564.21 | 1275 / 1335 | 0% | 0 | 0 / 0 |
adipose | 94% | 540.83 | 1126 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 72.09 | 41 / 45 |
heart | 49% | 184.45 | 423 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 31% | 7.37 | 25 / 80 |
muscle | 9% | 27.39 | 73 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0009615 | Biological process | response to virus |
GO_0016236 | Biological process | macroautophagy |
GO_0008637 | Biological process | apoptotic mitochondrial changes |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0016239 | Biological process | positive regulation of macroautophagy |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0010508 | Biological process | positive regulation of autophagy |
GO_0050821 | Biological process | protein stabilization |
GO_0007346 | Biological process | regulation of mitotic cell cycle |
GO_0006468 | Biological process | protein phosphorylation |
GO_0046777 | Biological process | protein autophosphorylation |
GO_0000082 | Biological process | G1/S transition of mitotic cell cycle |
GO_0005737 | Cellular component | cytoplasm |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PIM2 |
Protein name | Serine/threonine-protein kinase pim-2 (EC 2.7.11.1) (Pim-2h) non-specific serine/threonine protein kinase (EC 2.7.11.1) |
Synonyms | |
Description | FUNCTION: Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression, the regulation of cap-dependent protein translation and through survival signaling by phosphorylation of a pro-apoptotic protein, BAD. Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase transcriptional activity. The stabilization of MYC exerted by PIM2 might explain partly the strong synergism between these 2 oncogenes in tumorigenesis. Regulates cap-dependent protein translation in a mammalian target of rapamycin complex 1 (mTORC1)-independent manner and in parallel to the PI3K-Akt pathway. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Promotes cell survival in response to a variety of proliferative signals via positive regulation of the I-kappa-B kinase/NF-kappa-B cascade; this process requires phosphorylation of MAP3K8/COT. Promotes growth factor-independent proliferation by phosphorylation of cell cycle factors such as CDKN1A and CDKN1B. Involved in the positive regulation of chondrocyte survival and autophagy in the epiphyseal growth plate. . |
Accessions | ENST00000710069.1 ENST00000710360.1 A0AA34QVH7 Q9P1W9 ENST00000376509.4 |